Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
ND Kauff, RR Barakat - Journal of Clinical Oncology, 2007 - ascopubs.org
Women with mutations in BRCA1 or BRCA2 are at tremendously increased lifetime risk of
both breast and BRCA-associated gynecologic (ovarian, fallopian tube, and primary …
both breast and BRCA-associated gynecologic (ovarian, fallopian tube, and primary …
Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients
MD Schwartz, C Lerman, B Brogan… - Journal of Clinical …, 2004 - ascopubs.org
Purpose Approximately 5% to 10% of newly diagnosed breast cancer patients carry a
BRCA1 or BRCA2 mutation. Given these patients' high risk for contralateral breast cancer …
BRCA1 or BRCA2 mutation. Given these patients' high risk for contralateral breast cancer …
Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
K Armstrong, JS Schwartz, T Randall… - Journal of Clinical …, 2004 - ascopubs.org
Purpose The decision about prophylactic oophorectomy is difficult for many premenopausal
women with BRCA1/2 mutations because of concerns and controversy about the use of …
women with BRCA1/2 mutations because of concerns and controversy about the use of …
Effect of Prevention Strategies on Survival and Quality-Adjusted Survival of Women With BRCA1/2 Mutations: An Updated Decision Analysis
VR Grann, JS Jacobson, D Thomason… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: This study updates findings regarding the effects of prophylactic surgery,
chemoprevention, and surveillance on the survival and quality-adjusted survival of women …
chemoprevention, and surveillance on the survival and quality-adjusted survival of women …
Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation
H Meijers-Heijboer, CTM Brekelmans… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: To analyze the use of genetic testing, prophylactic mastectomy, and oophorectomy
among women with breast and/or ovarian cancer from families with a BRCA1 or BRCA2 …
among women with breast and/or ovarian cancer from families with a BRCA1 or BRCA2 …
Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians
BN Peshkin, C Isaacs, C Finch, S Kent… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To assess physician recommendations about the use of tamoxifen in
premenopausal BRCA1 and BRCA2 mutation carriers. Methods: We mailed surveys to a …
premenopausal BRCA1 and BRCA2 mutation carriers. Methods: We mailed surveys to a …
[PDF][PDF] Deliberate deceit of family members: a challenge to providers of clinical genetics services
JT Loud, NE Weissman, JA Peters, RM Giusti… - J Clin …, 2006 - researchgate.net
The proband was a 55-year-old white female who sought pretest counseling when she
learned that her father was a BRCA1 mutation carrier. Her father is 85 years old, in good …
learned that her father was a BRCA1 mutation carrier. Her father is 85 years old, in good …
[PDF][PDF] 中国乳腺癌患者BRCA1/2 基因检测与临床应用专家共识(2018 年版)
C PTEN - 中国癌症杂志, 2018 - china-oncology.com
中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识(2018年版) Page 1 《中国癌症杂志》2018年
第28卷第10期 CHINA ONCOLOGY 2018 Vol.28 No.10 787 欢迎关注本刊公众号 ·指南与共识 …
第28卷第10期 CHINA ONCOLOGY 2018 Vol.28 No.10 787 欢迎关注本刊公众号 ·指南与共识 …